PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Nasrallah, Henry A
ED  - Kramer, Michelle
ED  - Hough, David
TI  - Paliperidone Palmitate for the Treatment of Schizophrenia—Selected Posters
DP  - 2008 Nov 01
TA  - MD Conference Express
PG  - 14--14
VI  - 8
IP  - 3
4099  - http://mdc.sagepub.com/content/8/3/14.2.short
4100  - http://mdc.sagepub.com/content/8/3/14.2.full
AB  - Adherence to the use of oral forms of antipsychotic therapy, which usually require daily administration, is a major problem when treating patients with schizophrenia. Poor adherence is common and can lead to recurrence of symptoms and hospitalization. Paliperidone palmitate is a long-acting injectable formulation that may simplify the medication regimen for both patients and caregivers. This article discusses 3 double-blind, placebo-controlled randomized studies in patients with schizophrenia reported the efficacy and safety of 25, 50, or 100 mg equivalent paliperidone palmitate injected IM every 4 weeks.